Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

digital therapy

- PMLiVE

Celgene’s Revlimid scores NICE approval in follicular lymphoma

New ‘chemotherapy-free’ treatment for patients with limited options

- PMLiVE

Trial of Amgen, Servier’s heart failure drug clears interim check

Drug could become a $2bn product if approved

- PMLiVE

Servier and Oncodesign reach first milestone in Parkinson’s partnership

Oncodesign receives first success payment of €1m

- PMLiVE

NICE plans to widen the net for data it uses in guidance

Plans to include electronic health records and real-world evidence

- PMLiVE

NICE knocks back J&J’s depression nasal spray Spravato

Cites clinical and pricing uncertainty as basis of rejection

- PMLiVE

NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi

Initial guidance says drug is too costly but encourages further data

- PMLiVE

NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata

Cost-effectiveness watchdog issues a round of draft and final guidance

- PMLiVE

NICE rejects Akcea’s rare inherited disorder drug Waylivra

Draft guidance deems drug too costly for NHS use

- PMLiVE

NICE knocks back Roche’s Tecentriq for small cell lung cancer

Insufficient evidence to approve use in SCLC on the NHS

- PMLiVE

J&J gets EU approval for depression nasal spray Spravato

Approved with a risk management plan to guard dosing

- PMLiVE

Pfizer’s Ibrance scores second-line breast cancer approval via NICE’s Cancer Drugs Fund

Around 3,200 women in England could be eligible for treatment

- PMLiVE

NICE backs first cannabis-based drugs, both from GW Pharma

Approved to treat patients with epilepsy and multiple sclerosis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links